Positive Phase 1 results reported for the first orally active oxytocin antagonist OBE001 to treat preterm labour

ObsEva, a Swiss biopharmaceutical company developing a novel generation of drugs addressing serious conditions compromising pregnancy from conception to birth, has announced the results of a Phase… …read more